Autolus Therapeutics plc

Real-world data (RWD) and real-world evidence (RWE) have the potential to help support companies in demonstrating the value of novel therapies to payers in Europe, particularly in the gene therapy spa

Financing of UK biotech companies nearly doubled in 2024 compared with the year before, with £3.5bn ($4.34bn) being raised to support new and existing companies. That represented a 94% increase in tot

Seven new advanced therapy medicinal products (ATMPs) could be approved for pan-EU approval this year, based on data from the Pink Sheet’s EU regulatory filings tracker , including Roche / Sarepta

UK biotech company Autolus has gained its first ever drug approval in the shape of its CAR-T therapy Aucatzyl for use in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-AL